Citius Pharmaceuticals
CTXR
7 hedge funds and large institutions have $926K invested in Citius Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, 1 reducing their positions, and 3 closing their positions.
727% more capital invested
Capital invested by funds: $112K → $926K (+$814K)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
40% more funds holding
Funds holding: 5 → 7 (+2)
0.08% more ownership
Funds ownership: 0.02% → 0.1% (+0.08%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$842K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$48.1K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$44.3K |
| 4 |
HFM
Hartford Financial Management
Hartford,
Connecticut
|
+$2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$63K |
| 2 |
Goldman Sachs
New York
|
-$36K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.6K |
| 4 |
Morgan Stanley
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $820K | +$842K | +8,405 | New |
|
|
RJA
2
Raymond James & Associates
St Petersburg,
Florida
| $46K | +$48.1K | +480 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $43K | +$44.3K | +442 | New |
|
|
CP
4
Corbenic Partners
Bethlehem,
Pennsylvania
| $7K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $6K | -$1.6K | -16 | -21% |
|
|
DCM
6
Delpha Capital Management
New York
| $3K | +$3K | +30 | New |
|
|
HFM
7
Hartford Financial Management
Hartford,
Connecticut
| $1K | +$2K | +20 | New |
|
|
8
Millennium Management
New York
| – | -$63K | -799 | Closed |
|
|
9
Goldman Sachs
New York
| – | -$36K | -463 | Closed |
|
|
10
Morgan Stanley
New York
| – | -$1K | -8 | Closed |
|
CTXR Hedge Fund Activity: Q4 2017 in Review
7 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q4 2017, worth a combined $926K — up 727% from $112K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CTXR positions and 3 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $842K. The largest seller was Millennium Management, exiting entirely with an estimated $63K sold.
- 7 institutional investors held Citius Pharmaceuticals (CTXR) as of Q4 2017, up from 5 in Q3 2017.
- Funds reported $926K of Citius Pharmaceuticals stock for Q4 2017, up 727% quarter-over-quarter.
- 5 funds opened new Citius Pharmaceuticals positions in Q4 2017 and 3 closed out, a net change of +2 holders.
- The largest Citius Pharmaceuticals buyer in Q4 2017 was Sabby Management, an estimated $842K added.
- The largest Citius Pharmaceuticals seller in Q4 2017 was Millennium Management, an estimated $63K sold.
Based on aggregated 13F filings for Q4 2017.